新型植入式胫神经刺激器治疗膀胱过度活动症的3年随访
本研究对既往植入BlueWind RENOVA iStim系统的膀胱过度活动症患者进行3年延续随访,评估长期安全性与疗效。34例中20例同意继续参与,平均年龄56.1岁,女性占80%。36个月时总体治疗成功率为75%(符合方案集16例和意向治疗集20例),73%患者健康相关生活质量评分改善超过10分的最小重要差异。
要点
- 36个月总体治疗成功率为75%(符合方案集与意向治疗集分析)
- 73%患者健康相关生活质量评分改善超过最小重要差异10分
- 长期安全性良好,未报告技术故障相关的严重不良事件
核心结论
- 3年随访证实BlueWind RENOVA iStim系统治疗膀胱过度活动症具有长期良好安全性,无技术故障报告,疗效持续且对生活质量有积极影响。
研究设计与样本
- 对既往植入RENOVA系统的膀胱过度活动症患者进行延续性3年随访研究,共34例既往植入者中20例同意参与。
- 主要终点为基于系统或操作相关严重不良事件发生率和频率的安全性评估,次要终点包括36个月时3日排尿日记和生活质量问卷较基线的改善。
主要发现
- 36个月时总体治疗成功率为75%(符合方案集16例,意向治疗集20例)。
- 73%的患者报告健康相关生活质量评分改善超过最小重要差异10分。
- 平均年龄56.1岁,研究队列中女性占80%(16例)。
临床怎么用
- 对于膀胱过度活动症患者,植入式胫神经刺激器可作为维持长期疗效和生活质量改善的治疗选择。
局限性
- 样本量较小,仅20例参与3年随访,可能影响结果的普遍性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We evaluated the 3-year safety and efficacy of the BlueWind Medical RENOVA™ iStim system for the treatment of overactive bladder syndrome. MATERIALS AND METHODS: All patients who previously underwent implantation with the RENOVA system were offered continued participation. The primary long-term study end point was to evaluate the safety profile based on incidence of serious adverse events (system and/or procedure related), which was measured by the impact and frequency of serious adverse events. The secondary end points included clinical improvement compared to baseline and quality of life improvement compared to baseline at 36 months, which was measured by 3-day voiding diary and quality of life questionnaires at certain time points. RESULTS: Of the 34 patients with overactive bladder syndrome who previously underwent implantation with the RENOVA system 20 consented to continuation in this 3-year followup study. Mean patient age was 56.1 years and 80% (16) of the study cohort was female. The overall treatment success rate was 75% at 36 months in the per protocol (16) and the intent to treat (20) analyses. In total, 73% of the patients reported improvement in health related quality of life scores above the minimal important difference of 10 points. CONCLUSIONS: This 3-year followup study using the BlueWind RENOVA iStim system for the treatment of overactive bladder syndrome symptoms confirms the long-term good safety profile with no technical failures reported. Lasting treatment efficacy is mirrored by a sustained positive impact on patient quality of life.
引用
- Dorsthorst MJT, Digesu GA, Tailor V, et al. 3-Year Followup of a New Implantable Tibial Nerve Stimulator for the Treatment of Overactive Bladder Syndrome. J Urol. 2020. PMID: 32271689. doi:10.1097/JU.0000000000001024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。